Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials
#5PRI RANKED
Most Cited Paper
in Heart Failure Treatment and Management
18 Months Post-Publication
Class of 2026
“Semaglutide versus placebo in patients with heart failure and mildly reduced or preserved ejection fraction: a pooled analysis of the SELECT, FLOW, STEP-HFpEF, and STEP-HFpEF DM randomised trials”
A research intelligence initiative by Pepkio
pri.pepkio.com
Topics
semaglutide · Heart failure with preserved ejection fraction · Heart failure with mildly reduced ejection fraction · SELECT trial · FLOW trial · STEP-HFpEF trial · STEP-HFpEF DM trial · Patient-level pooled analysis · GLP-1 receptor agonist · Left ventricular ejection fraction · cardiovascular outcomes · obesity-related heart failure · type 2 diabetes · Heart failure with preserved ejection fraction · Heart failure with mildly reduced ejection fraction
Share
Cite this ranking
Pepkio Research Index (PRI). Topics and Trends in Most Cited Heart Failure Treatment and Management Papers, Class of 2026. https://pri.pepkio.com/top-papers/heart-failure-treatment-and-management/2026. Accessed 2026-08-20. Methodology Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459